On February 14, 2018 Celltrion, Inc. (KRX:068270) reported that the European Commission (EC) approved Herzuma (trastuzumab biosimilar) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification (Press release, Celltrion, FEB 14, 2018, View Source [SID1234523957]). The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on December 14, 2017.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The development of biosimilar is of great importance in the field of oncology, and has the potential to enrich our therapeutic arsenal against a variety of diseases and to increase patients’ accessibility to innovative drugs at a more affordable price," said Woosung Kee, Chief Executive Officer of Celltrion. "We have already seen many benefits of biosimilars in Europe from our experience with Remsima and Truxima[1]. Our experience has shown that biosimilars not only reduce individual patient’s out-of-pocket medical expenses but also contribute to lowering financial burden on insurance payers and national health agencies."
The European Commission’s approval of Herzuma marks an important milestone for Celltrion, providing more treatment options for patients. Herzuma is the third biosimilar from Celltrion’s portfolio approved by the EC.
This decision by the European Commission means that Herzuma is now approved for marketing in the 28 member states of the European Union (EU), in addition to Norway, Liechtenstein and Iceland.
About Herzuma
Herzuma is an anticancer monoclonal antibody (mAb) biosimilar drug used to treat breast cancer and gastric cancer. Similarity of Herzuma to the reference product, Herceptin[2], was demonstrated in terms of pharmacokinetic, pharmacodynamics, efficacy and safety through multiple global clinical trials. In 2017, Celltrion launched Herzuma in Korea.